Anti-interleukin-33 antibodies and uses thereof
AssigneeGenentech, Inc.
InventorsPhilip E. Hass, Meredith Hazen, Yi-Chun Hsiao, Rajita Khosla, Gerald R. Nakamura, Dhaya Seshasayee, Menno Van Lookeren Campagne, Hongkang Xi, Wenwu Zhai, Jack Bevers, III, Nancy Chiang
Life of this patent
Estimating the term…
Abstract
The invention provides interleukin-33 (IL-33) antibodies and methods of using the same.
Claims58
An isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising the following six HVRs:
- (a) an HVR-H1 comprising the amino acid sequence of SFSX1S (SEQ ID NO:
- 62), wherein X1 is Met, Leu, or Val;
- (b) an HVR-H2 comprising the amino acid sequence of TISGGKTFTDYVDXNKG (SEQ ID NO:
- 63), wherein X1 is Ser or Ala;
- (c) an HVR-H3 comprising the amino acid sequence of ANYGX1X2FFEV (SEQ ID NO:
- 64), wherein X1 is Asn or Asp, and X2 is Trp or Phe;
- (d) an HVR-L1 comprising the amino acid sequence of RASESVAKYGLSLLN (SEQ ID NO:
- 4);
- (e) an HVR-L2 comprising the amino acid sequence of AASNRGS (SEQ ID NO:
- 5);
- and
- (f) an HVR-L3 comprising the amino acid sequence of QQSKEVPFT (SEQ ID NO:
- 6).
An isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising (a) a heavy chain variable (VH) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:
- 36 and (b) a light chain variable (VL) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:
- 37.
An isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence of SEQ ID NO:
- 36 and (b) a VL domain comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence of SEQ ID NO:
- 37.
An isolated antibody that specifically binds IL-33, wherein the antibody comprises (a) a heavy chain comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence of SEQ ID NO:
- 288 and (b) a light chain comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence of SEQ ID NO:
- 289.
An isolated antibody that specifically binds IL-33, wherein the antibody comprises (a) a heavy chain comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence of SEQ ID NO:
- 290 and (b) a light chain comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence of SEQ ID NO:
- 291.
An isolated antibody that specifically binds both IL-33 and IL-13, wherein the antibody comprises a first binding domain that specifically binds IL-33 comprising the following six HVRs:
- (a) an HVR-H1 comprising the amino acid sequence of SFSMS (SEQ ID NO:
- 1);
- (b) an HVR-H2 comprising the amino acid sequence of TISGGKTFTDYVDSVKG (SEQ ID NO:
- 2);
- (c) an HVR-H3 comprising the amino acid sequence of ANYGNWFFEV (SEQ ID NO:
- 3);
- (d) an HVR-L1 comprising the amino acid sequence of RASESVAKYGLSLLN (SEQ ID NO:
- 4);
- (e) an HVR-L2 comprising the amino acid sequence of AASNRGS (SEQ ID NO:
- 5);
- and
- (f) an HVR-L3 comprising the amino acid sequence of QQSKEVPFT (SEQ ID NO:
- 6);
- and
- a second binding domain that specifically binds IL-13 comprising the following six HVRs:
- (a) an HVR-H1 comprising the amino acid sequence of AYSVN (SEQ ID NO:
- 296);
- (b) an HVR-H2 comprising the amino acid sequence of MIWGDGKIVYNSALKS (SEQ ID NO:
- 297);
- (c) an HVR-H3 comprising the amino acid sequence of DGYYPYAMDN (SEQ ID NO:
- 298);
- (d) an HVR-L1 comprising the amino acid sequence of RASKSVDSYGNSFMH (SEQ ID NO:
- 299);
- (e) an HVR-L2 comprising the amino acid sequence of LASNLES (SEQ ID NO:
- 300);
- and
- (f) an HVR-L3 comprising the amino acid sequence of QQNNEDPRT (SEQ ID NO:
- 301).
Dependencies are inferred from the claim text.